Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia.

Leukemia research - 1 Jan 2009

Begleiter Asher, Hewitt Donna, Gibson Spencer B, Johnston James B

Abstract excerpt

NAD(P)H:quinoneoxidoreductase 1 (NQO1) inhibits some cancers and increases p53 and apoptosis in cells. Due to an inactivating polymorphism, 10% of humans have no NQO1 activity. A case:control study suggested that chronic lymphocytic leukemia (CLL) patients may have an increased incidence of the NQO1 null genotype compared with controls. NQO1 genotype did not correlate with various CLL prognostic factors, but we...

Topics

Adult
Aged
Aged, 80 and over
Case-Control Studies
Female
Genotype
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
NAD(P)H Dehydrogenase (Quinone)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polymorphism, Genetic

Prognosis

Risk Factors

Source

Identifiers

PMID: 18676018
DOI: 10.1016/j.leukres.2008.06.030

Genes

NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-18676018-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia.PMID 18676018Read ↗

Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.Semantic proximity Read ↗

Effects of the NQO1 609C>T polymorphism on leukemia susceptibility: evidence from a meta-analysis.Semantic proximity Read ↗

Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1).Semantic proximity Read ↗

NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis.Semantic proximity Read ↗

UGT1A1*28 polymorphism in chronic lymphocytic leukemia: the first investigation of the polymorphism in disease susceptibility and its specific cytogenetic abnormalities.Semantic proximity Read ↗

Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis.Semantic proximity Read ↗

Q192R and L55M Polymorphisms of Paraoxonase 1 Gene in Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

An association between a NQO1 genetic polymorphism and risk of lung cancer.Semantic proximity Read ↗

Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults.Semantic proximity Read ↗

NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review.Semantic proximity Read ↗

A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.Semantic proximity Read ↗

Detection of quinone oxidoreductase 1 (NQO1) single-nucleotide polymorphisms (SNP) related to benzene metabolism in immortalized B lymphocytes from a Chinese Han population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.